Scientists raise warnings over MS drug study risks
American scientists are raising a red warning flag over proposed studies of the drug minocycline for several neurodegenerative conditions. Reporting in Lancet Neurology, the researchers say that patients taking the off-patent minocycline for Lou Gehrig's disease declined more rapidly than the control group taking a placebo. That report comes as Canada's MS Society is funding a Phase III trial to determine if the drug can work to slow MS if it is administered during the early stage of the disease.
- check out the report from the Canadian Press
Related Articles:
Antibody stimulates natural repair of MS damage. Report
Natural protein used to combat multiple sclerosis. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
